Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening
- 주제(키워드) article , cancer diagnosis , cancer grading , cancer screening , comparative study , controlled study , cytology , diagnostic kit , diagnostic test accuracy study , DNA determination , female , genotype , histopathology , human , human cell , human papillomavirus screening real time polymerase chain reaction , Human papillomavirus type 16 , Human papillomavirus type 18 , hybrid capture high risk papillomavirus DNA test , intermethod comparison , major clinical study , nonhuman , priority journal , real time high risk human papillomavirus test , sensitivity and specificity , uterine cervix cancer , uterine cervix carcinoma in situ , virus detection , Wart virus
- 등재 SCOPUS
- 발행기관 Elsevier
- 발행년도 2014
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000096968
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.jviromet.2014.04.021
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
The clinical performance of three human papillomavirus (HPV) DNA commercial assays for cervical cancer screening was evaluated; the AdvanSure HPV Screening Real-Time PCR (AdvanSure PCR; LG Life Sciences) that was developed recently for the detection of both high-risk and low-risk genotypes, the Abbott RealTime High-Risk HPV Test (Abbott PCR; Abbott Molecular) and the Hybrid Capture High-Risk HPV DNA test (HC2; Qiagen). The three different HPV DNA tests were compared using cytology samples obtained from 619 women who underwent routine cervical cancer screening. The gold-standard assay was histopathological confirmation of cervical intraepithelial neoplasia of grade 2 or worse. The clinical sensitivities of the AdvanSure PCR, the Abbott PCR and the HC2 for the detection of cervical intraepithelial neoplasia of grade 2 or worse were 95.5%, 95.5% and 100%, respectively, while the clinical specificities were 61.6%, 86.4% and 83.3%, respectively. There were no significant differences in the clinical sensitivities of the Abbott PCR and the AdvanSure PCR compared to the HC2. The clinical specificities of the Abbott PCR and the AdvanSure PCR for the detection of HPV types 16/18 were 97.8% and 98.5%, respectively. For cervical cancer screening, all three tests showed relatively good clinical sensitivities, but the AdvanSure PCR had lower clinical specificity than the Abbott PCR and the HC2. The AdvanSure PCR and the Abbott PCR assays have the advantage of being automated and the ability to distinguish between HPV types 16/18 and other HPV types. The two real-time PCR assays could be useful tools in HPV testing for cervical cancer screening.
more